Abstract
The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clinical Pathology and the American Society of Clinical Oncology jointly published guidelines for HER2 testing and clinical decision making in gastro-oesophageal adenocarcinoma. The Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee has issued the following document as a commentary of these guidelines and, in parallel, to provide guidance on HER2 testing in National Health Service pathology departments within the UK. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such HER2 testing.
| Original language | English |
|---|---|
| Pages (from-to) | 388-394 |
| Number of pages | 7 |
| Journal | Journal of Clinical Pathology |
| Volume | 71 |
| Issue number | 5 |
| Early online date | 8 Feb 2018 |
| DOIs | |
| Publication status | Published - 1 May 2018 |
Keywords
- adenocarcinoma stomach
- guidance
- HER2
- immunohistochemistry
- in-situ hybridisation
- oesophagus
Access to Document
- Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via BMJ Publishing at http://jcp.bmj.com/content/71/5/388 . Please refer to any applicable terms of use of the publisher.